# OneSource Specialty Pharma share price today (OneSource Specialty Pharma Ltd, NSE: ONESOURCE)

> OneSource Specialty Pharma share price today: ₹1,568.70 at the NSE close on 3 November 2026, down 15.4% in a year. OneSource Specialty Pharma (NSE: ONESOURCE) is worth ₹17,989 crore, trades at a P/E of 1,572.7 and has closed between ₹1,114.00 and ₹1,837.90 over the past 52 weeks. > OneSource Specialty Pharma Ltd's results are improving, and its P/E is near the top of its own history, higher than 100% of past readings. ONESOURCE · Pharma - API & CRAMS · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/onesource-specialty-pharma-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: ₹1,568.70 (−15.4% in a year)
- P/E: 1,572.7× (higher than 100% of the last 1 year)
- Revenue (Sep 2026): ₹516 Cr (+37.2% on a year ago)
- Profit (Sep 2026): ₹57.0 Cr (+470.0% on a year ago)
- Operating margin: 32.0% (+4.0 points on a year ago)
- ROCE: 1%, FY26

The main question: results are strong, and the P/E is higher than 100% of its own history. ## What is the OneSource Specialty Pharma share price today? OneSource Specialty Pharma Ltd's share price was ₹1,568.70 at the close on 3 November 2026. It has been falling for 11 weeks. That is 1.3% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹1,114 and ₹1,838, and at that close it sat 63% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 2 weeks in a row. Over the last 1 year the share price moved −8% while the NIFTY 500 moved +3%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at OneSource Specialty Pharma this quarter? Three changes stood out: indian funds and insurers (DIIs) raised their stake for 7 quarters in a row, started beating the market again after 13 weeks behind it and highest quarterly revenue in 13 quarters. 1. Indian funds and insurers (DIIs) raised their stake for 7 quarters in a row From 12.6% to 24.2% of the company by the September 2026 quarter. 2. Started beating the market again after 13 weeks behind it
3. Highest quarterly revenue in 13 quarters Revenue of ₹516 crore in the September 2026 quarter is the highest of the last 13 quarters. Why: The September quarter was the best in 13 quarters because the second cartridge line started making commercial batches in September, adding more production of sterile medicines. Next results: check whether the third cartridge line passes site checks and starts making commercial batches in the expected window. From the earnings call on 27 Oct 2026. ## What are OneSource Specialty Pharma's latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), OneSource Specialty Pharma reported revenue of ₹516 crore, up 37.2% from ₹376 crore a year earlier, and a profit of ₹57.0 crore, up 470.0% from ₹10.0 crore. ### OneSource Specialty Pharma results: July to September 2026 against a year earlier

| Measure | July to September 2026 | July to September 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹516 crore | ₹376 crore | +37.2% |
| Profit | ₹57.0 crore | ₹10.0 crore | +470.0% |
| Earnings per share | ₹5.01 | ₹0.92 | +444.6% |
| Operating margin | 32.0% | 28.0% | +4.0 points |

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). OneSource Specialty Pharma's management discussed these results on a call held on 27 October 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.)

## What is the OneSource Specialty Pharma share price history? OneSource Specialty Pharma closed at ₹1,568.70 on 3 November 2026, down 15.4% from ₹1,854.10 a year earlier (31 October 2025). Its highest weekly close since January 2025 was ₹2,194.00 on 27 June 2025. ### OneSource Specialty Pharma share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹1,334.10 | +17.6% |
| 1 month ago · 1 Oct 2026 | ₹1,508.00 | +4.0% |
| 6 months ago · 30 Apr 2026 | ₹1,738.10 | −9.7% |
| 1 year ago · 31 Oct 2025 | ₹1,854.10 | −15.4% |
| Earliest weekly close in our records · 24 Jan 2025 | ₹1,710.00 | −8.3% |
| Highest weekly close since January 2025 · 27 Jun 2025 | ₹2,194.00 | −28.5% |
| Lowest weekly close since January 2025 · 6 Feb 2026 | ₹1,119.90 | +40.1% |
| 52-week high (weekly close) · 4 Jun 2026 | ₹1,837.90 | −14.6% |
| 52-week low (weekly close) · 29 Jan 2026 | ₹1,114.00 | +40.8% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (100 weekly closes from 24 January 2025 to 3 November 2026.)

## What is the latest news on OneSource Specialty Pharma? 3 Nov 2026: OneSource Specialty Pharma closed at ₹1,568.70, up 17.6% on the week and up 4.0% on the month. 27 Oct 2026: OneSource Specialty Pharma held its results call for July to September 2026. Management guided: FY28 revenue USD 400M with reported operating profit USD 160M reaffirmed. ### Earlier

- Results for July to September 2026: Revenue up 37.2% and profit up 470.0% on a year earlier. ## What dividend does OneSource Specialty Pharma pay? OneSource Specialty Pharma has paid no dividend on the NSE since its first NSE close in our records (24 January 2025), the start of the period we checked. No. OneSource Specialty Pharma Ltd paid out 0% of its profit as dividends in each of its last 6 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate. (From the NSE corporate-actions record, read 4 November 2026.)

## What did OneSource Specialty Pharma management say on the latest results call? On the call for July to September 2026, held on 27 October 2026, OneSource Specialty Pharma's management guided: FY28 revenue USD 400M with reported operating profit USD 160M reaffirmed. > “Every one of our lines is backed by full end-to-end capabilities, including not only cartridge filling but also assembly, labeling, packaging, and so on, including cold chain, all under one roof. - Neeraj”
> CEO and MD, on the call for July to September 2026

### What management guided

- H2FY27 stronger than H1FY27 on launches and commercial ramp. - All three DDC lines operational and available for FY28; Line 3 Q4 effort with possible early FY28 start. - ETR to stay at current level through October to December 2027 on brought-forward losses. - Debt around 1.5x operating profit with ROCE in high-20s by end FY28. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijoristack.ai/concall/transcript/58746-27-Oct-2026.pdf). (From the call for July to September 2026, 27 October 2026.)

## What to watch in OneSource Specialty Pharma's next results? When OneSource Specialty Pharma reports October to December 2026, these are the 4 checks that show whether the story is still on course. First: Line 3 progress from site qualification to commercial batches against guided window - check for further slip language. - What to check (from the call)
- Line 3 progress from site qualification to commercial batches against guided window - check for further slip language. - H2 strength versus H1 on Canada relaunch shipments and other Canadian ramp plus new launches - check commercial conversion. - Injectables new lyophilization and prefilled syringe readiness after shutdown - check availability and order fill. - Customer approvals in Brazil and Turkey against expected timeline - check conversion to supply start. ## Which stock lists is OneSource Specialty Pharma on? OneSource Specialty Pharma is on 2 of our India lists: Small & mid cap stocks and Pharma stocks. - [Small & mid cap stocks Size rank in India: 375](https://www.sectoralpha.in/small-cap-stocks-india)
- [Pharma stocks Market value (₹ crore): 17868.955086372363](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is OneSource Specialty Pharma profitable? OneSource Specialty Pharma Ltd earned ₹57.0 Cr of net profit in the Sep 2026 quarter, +470.0% on the same quarter a year earlier. The full FY26 year was a loss of ₹74.0 Cr. That is 11.0% of the quarter's revenue. The same quarter a year earlier earned ₹10.0 Cr. 6 of the last 12 reported quarters were loss-making. ## How much revenue does OneSource Specialty Pharma make, and is it growing? OneSource Specialty Pharma Ltd reported ₹516 Cr of revenue in the Sep 2026 quarter, +37.2% on the same quarter a year earlier. That is the 3rd quarter in a row with growth on the year before. Over 5 years it has grown 132.3% a year on average. The last full year, FY26, came in at ₹1,422 Cr. The last four reported quarters add to ₹1,683 Cr. FY26 revenue was ₹1,422 Cr, −1.6% on the year before. Recent pace: the last four quarters grew +12.2% on average, against 132.3% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +10.6%, against +49.3% a year over the last 8 quarters (rolling over). ## How much of every ₹100 of sales does OneSource Specialty Pharma keep? OneSource Specialty Pharma Ltd's operating margin was 32.0% in the Sep 2026 quarter, 4.0 percentage points higher than the same quarter a year ago. Across 6 years it has been between −415.0% and 32.0%. The latest quarter is within that range. Why the margin moved: operating margin changed +3.3 percentage points on the year while gross margin changed +1.0 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is OneSource Specialty Pharma's profit turning into cash? OneSource Specialty Pharma Ltd's cash-flow history is too short to judge how much of its profit turns into cash. In FY26 it brought in ₹9.0 Cr of operating cash against −₹74.0 Cr of profit. After ₹489 Cr of spending on assets, free cash was −₹480 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does OneSource Specialty Pharma's cash go? OneSource Specialty Pharma Ltd's customer, stock and supplier day counts come out in the thousands of days on sales this small (₹1,422 Cr in FY26), so no cash-cycle chart is drawn and this section looks at its spending on assets instead. It spent ₹5,480 Cr on assets over the last 3 years. Averaged over those years that is 128.5% of FY26 revenue a year. Spending on assets: ₹5,480 Cr over the last 3 years, against ₹629 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹529 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is OneSource Specialty Pharma's P/E ratio, and how does it compare with its own history? OneSource Specialty Pharma Ltd's P/E is 1,572.7×, about the highest it has ever been. Its usual P/E (the middle reading) is 240.5×, over 1 year of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the OneSource Specialty Pharma business getting better or worse? OneSource Specialty Pharma Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 10 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does OneSource Specialty Pharma earn on its capital? OneSource Specialty Pharma Ltd earned a ROCE of 1% in FY26. That is up from a low of −12% in FY23. Its return on capital used (ROIC) is 11.3 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −5.2% net margin and 0.17× asset turnover (sales divided by assets). Why the return is what it is (FY26): a −5.2% net margin × 0.17× asset turnover × 1.42× leverage (assets divided by equity) ≈ −1.3% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 0.7% − 12.0% = −11.3 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does OneSource Specialty Pharma have too much debt? OneSource Specialty Pharma Ltd has total debt of ₹1,755 Cr against shareholder equity of ₹5,921 Cr as of Sep 2026, so its debt is 0.30× its equity, which is very little. Year by year, that ratio went from 1.44 in FY24 to 0.26 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the OneSource Specialty Pharma shareholding pattern? Domestic institutions raised their stake in OneSource Specialty Pharma Ltd by 11.6 percentage points over 7 quarters, the biggest change among its owners. Domestic institutions now own 24.2% of the company. Promoters moved −7.3 points over the same period, to 30.5%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Domestic institutions: +11.6 points over 7 quarters, to 24.2%; Promoters: −7.3 points over 7 quarters, to 30.5%; Foreign institutions: +2.0 points over 7 quarters, to 19.4%. Why the owners changed: domestic institutions drove it (+11.6 points), with the other side taken by promoters (−7.3 points). They raised their stake step by step. ## How far is OneSource Specialty Pharma from balance-sheet trouble? For OneSource Specialty Pharma Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does OneSource Specialty Pharma rank in its industry? 29.2 out of 100, rank 21 of 24 in Pharma - API & CRAMS, with 83% of the evidence available. OneSource Specialty Pharma Ltd scores 29.2 out of 100 against the 24 companies it is compared with in Pharma - API & CRAMS, ranking 21. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 12.4 + 4.1 + 8.5 + 4.2 = 29.2. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is OneSource Specialty Pharma compared with? OneSource Specialty Pharma ranks 21 of 24 Pharma - API & CRAMS companies on the 4-Factor Sector Score, with 29.2 out of 100. 1. [Neuland Laboratories Ltd](https://www.sectoralpha.in/stocks/neuland-laboratories-ltd) NEULANDLAB · leader · Most evidence points up · 96% evidence 76.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 32.3/35 · Revenue 78.3% · Profit 100% · Operating margin change 23 points · 88% evidence Capital efficiency 22.9/25 · ROCE 26.5% · Operating margin 35% · 100% evidence Valuation 14.1/20 · P/E 50.8× · PEG 1.04 · 100% evidence Relative strength 6.7/20 · Lead over its industry -7.8% · Lead over NIFTY 500 20.3% · 1 year 19.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 32.3 + 22.9 + 14.1 + 6.7 = 76 · What this means: Earnings are strong; relative strength in its sector is -7.8% and the one-year return is 19.6%. 2. [Acutaas Chemicals Ltd](https://www.sectoralpha.in/stocks/acutaas-chemicals-ltd) ACUTAAS · turning · Most evidence points up · 67% evidence 73.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.3/35 · Revenue 45.4% · Profit 95.5% · Operating margin change 9 points · 95% evidence Capital efficiency 20.3/25 · ROCE 31.6% · Operating margin 40% · 76% evidence Valuation 10.2/20 · P/E 74.6× · PEG n/a · 50% evidence Relative strength 12.1/20 · Lead over its industry n/a · Lead over NIFTY 500 59.6% · 1 year 131.7% · 25% evidence · 2 of 9 weeks ahead Exact sum: 31.3 + 20.3 + 10.2 + 12.1 = 73.9 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Laurus Labs Ltd](https://www.sectoralpha.in/stocks/laurus-labs-ltd) LAURUSLABS · leader · Most evidence points up · 93% evidence 71.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.9/35 · Revenue 23% · Profit 95.3% · Operating margin change 10 points · 100% evidence Capital efficiency 17.3/25 · ROCE 17.8% · Operating margin 34% · 100% evidence Valuation 5.8/20 · P/E 97× · PEG 2.98 · 65% evidence Relative strength 17.0/20 · Lead over its industry 42.3% · Lead over NIFTY 500 82.8% · 1 year 152.2% · 100% evidence · 12 of 12 weeks ahead Exact sum: 30.9 + 17.3 + 5.8 + 17 = 71 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 4. [Gland Pharma Ltd](https://www.sectoralpha.in/stocks/gland-pharma-ltd) GLAND · leader · Most evidence points up · 96% evidence 69.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.0/35 · Revenue 17.6% · Profit 46.4% · Operating margin change 3 points · 88% evidence Capital efficiency 16.0/25 · ROCE 15.1% · Operating margin 27% · 100% evidence Valuation 12.1/20 · P/E 44.6× · PEG 1.45 · 100% evidence Relative strength 16.8/20 · Lead over its industry 15.1% · Lead over NIFTY 500 49.3% · 1 year 60.5% · 100% evidence · 12 of 12 weeks ahead Exact sum: 25 + 16 + 12.1 + 16.8 = 69.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [IOL Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/iol-chemicals-pharmaceuticals-ltd) IOLCP · leader · Most evidence points up · 100% evidence 69.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.1/35 · Revenue 26.7% · Profit 75% · Operating margin change 4 points · 100% evidence Capital efficiency 12.8/25 · ROCE 11.3% · Operating margin 14% · 100% evidence Valuation 13.9/20 · P/E 24.6× · PEG 0.66 · 100% evidence Relative strength 13.9/20 · Lead over its industry 21.6% · Lead over NIFTY 500 53.8% · 1 year 92.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 29.1 + 12.8 + 13.9 + 13.9 = 69.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Shilpa Medicare Ltd](https://www.sectoralpha.in/stocks/shilpa-medicare-ltd) SHILPAMED · leader · Most evidence points up · 89% evidence 67.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.4/35 · Revenue 28% · Profit 100% · Operating margin change 1 points · 88% evidence Capital efficiency 10.8/25 · ROCE 10.9% · Operating margin 29% · 100% evidence Valuation 9.9/20 · P/E 65.7× · PEG 1.73 · 65% evidence Relative strength 19.9/20 · Lead over its industry 47.2% · Lead over NIFTY 500 84.2% · 1 year 170.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 26.4 + 10.8 + 9.9 + 19.9 = 67 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Morepen Laboratories Ltd](https://www.sectoralpha.in/stocks/morepen-laboratories-ltd) MOREPENLAB · leader · Evidence leans up · 85% evidence 62.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.8/35 · Revenue 30.1% · Profit 90.9% · Operating margin change 9 points · 100% evidence Capital efficiency 9.3/25 · ROCE 8.1% · Operating margin 16% · 100% evidence Valuation 8.5/20 · P/E 32.9× · PEG 2.14 · 100% evidence Relative strength 12.5/20 · Lead over its industry n/a · Lead over NIFTY 500 94.5% · 1 year 139% · 25% evidence · 12 of 12 weeks ahead Exact sum: 31.8 + 9.3 + 8.5 + 12.5 = 62.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Divis Laboratories Ltd](https://www.sectoralpha.in/stocks/divis-laboratories-ltd) DIVISLAB · leader · Evidence leans up · 96% evidence 61.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.7/35 · Revenue 16.4% · Profit 26.8% · Operating margin change 11 points · 88% evidence Capital efficiency 18.6/25 · ROCE 22% · Operating margin 41% · 100% evidence Valuation 2.6/20 · P/E 87.1× · PEG 3.45 · 100% evidence Relative strength 15.5/20 · Lead over its industry 9.2% · Lead over NIFTY 500 43.1% · 1 year 45.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24.7 + 18.6 + 2.6 + 15.5 = 61.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 9. [Granules India Ltd](https://www.sectoralpha.in/stocks/granules-india-ltd) GRANULES · turning · Evidence leans up · 96% evidence 57.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.3/35 · Revenue 24.8% · Profit 38.1% · Operating margin change 3 points · 88% evidence Capital efficiency 16.2/25 · ROCE 15.5% · Operating margin 23% · 100% evidence Valuation 10.2/20 · P/E 35.2× · PEG 1.29 · 100% evidence Relative strength 6.7/20 · Lead over its industry -5.2% · Lead over NIFTY 500 24.2% · 1 year 48.5% · 100% evidence · 7 of 12 weeks ahead Exact sum: 24.3 + 16.2 + 10.2 + 6.7 = 57.4 · What this means: Earnings are strong; relative strength in its sector is -5.2% and the one-year return is 48.5%. 10. [Sai Life Sciences Ltd](https://www.sectoralpha.in/stocks/sai-life-sciences-ltd) SAILIFE · leader · Evidence leans up · 89% evidence 57.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.7/35 · Revenue 17.6% · Profit 48% · Operating margin change 3 points · 88% evidence Capital efficiency 17.0/25 · ROCE 19.6% · Operating margin 27% · 100% evidence Valuation 4.8/20 · P/E 90× · PEG 3.63 · 65% evidence Relative strength 13.8/20 · Lead over its industry 9.9% · Lead over NIFTY 500 42.9% · 1 year 69.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21.7 + 17 + 4.8 + 13.8 = 57.3 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 11. [SMS Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/sms-pharmaceuticals-ltd) SMSPHARMA · breaking out · Evidence leans up · 96% evidence 55.8 out of 100 Growth Capital Valuation Relative
12. [Blue Jet Healthcare Ltd](https://www.sectoralpha.in/stocks/blue-jet-healthcare-ltd) BLUEJET · quiet · Evidence leans up · 81% evidence 52.7 out of 100 Growth Capital Valuation Relative
13. [Solara Active Pharma Sciences Ltd](https://www.sectoralpha.in/stocks/solara-active-pharma-sciences-ltd) SOLARA · breaking out · Evidence leans down · 74% evidence 49.5 out of 100 Growth Capital Valuation Relative
14. [Windlas Biotech Ltd](https://www.sectoralpha.in/stocks/windlas-biotech-ltd) WINDLAS · leader · Evidence leans down · 81% evidence 47.6 out of 100 Growth Capital Valuation Relative
15. [Anthem Biosciences Ltd](https://www.sectoralpha.in/stocks/anthem-biosciences-ltd) ANTHEM · leader · Evidence leans down · 89% evidence 46.7 out of 100 Growth Capital Valuation Relative
16. [Piramal Pharma Ltd](https://www.sectoralpha.in/stocks/piramal-pharma-ltd) PPLPHARMA · leader · Evidence leans down · 71% evidence 44.6 out of 100 Growth Capital Valuation Relative
17. [Supriya Lifescience Ltd](https://www.sectoralpha.in/stocks/supriya-lifescience-ltd) SUPRIYA · breaking out · Evidence leans down · 96% evidence 43.7 out of 100 Growth Capital Valuation Relative
18. [Concord Biotech Ltd](https://www.sectoralpha.in/stocks/concord-biotech-ltd) CONCORDBIO · quiet · Evidence leans down · 85% evidence 40.8 out of 100 Growth Capital Valuation Relative
19. [Jubilant Pharmova Ltd](https://www.sectoralpha.in/stocks/jubilant-pharmova-ltd) JUBLPHARMA · turning · Most evidence points down · 86% evidence 30.3 out of 100 Growth Capital Valuation Relative
20. [Hikal Ltd](https://www.sectoralpha.in/stocks/hikal-ltd) HIKAL · turning · Most evidence points down · 78% evidence 29.7 out of 100 Growth Capital Valuation Relative
21. OneSource Specialty Pharma Ltd this page ONESOURCE · turning · Most evidence points down · 83% evidence 29.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 12.4/35 · Revenue 10.6% · Profit -80% · Operating margin change 4 points · 100% evidence Capital efficiency 4.1/25 · ROCE 0.6% · Operating margin 32% · 100% evidence Valuation 8.5/20 · P/E 1567× · PEG n/a · 15% evidence Relative strength 4.2/20 · Lead over its industry -22.4% · Lead over NIFTY 500 3.8% · 1 year -15.7% · 100% evidence · 1 of 12 weeks ahead Exact sum: 12.4 + 4.1 + 8.5 + 4.2 = 29.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 22. [Syngene International Ltd](https://www.sectoralpha.in/stocks/syngene-international-ltd) SYNGENE · turning · Most evidence points down · 100% evidence 27.8 out of 100 Growth Capital Valuation Relative
23. [Cohance Lifesciences Ltd](https://www.sectoralpha.in/stocks/cohance-lifesciences-ltd) COHANCE · breaking out · Most evidence points down · 78% evidence 27.1 out of 100 Growth Capital Valuation Relative
24. [Dishman Carbogen Amcis Ltd](https://www.sectoralpha.in/stocks/dishman-carbogen-amcis-ltd) DCAL · basing · Most evidence points down · 64% evidence 27.0 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - API & CRAMS](https://www.sectoralpha.in/sectors/pharma-api-crams), all 24 compared on one page. ## Which companies are close to OneSource Specialty Pharma in size? OneSource Specialty Pharma is the 11th largest of 24 Pharma - API & CRAMS companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Neuland Laboratories, Granules India and Shilpa Medicare. Just below it: Cohance Lifesciences, Syngene International and Jubilant Pharmova. ### Pharma - API & CRAMS companies close in size

1. [Neuland Laboratories Ltd](https://www.sectoralpha.in/stocks/neuland-laboratories-ltd) ₹25,275 crore
2. [Granules India Ltd](https://www.sectoralpha.in/stocks/granules-india-ltd) ₹22,907 crore
3. [Shilpa Medicare Ltd](https://www.sectoralpha.in/stocks/shilpa-medicare-ltd) ₹18,690 crore
4. OneSource Specialty Pharma Ltd ₹17,924 crore
5. [Cohance Lifesciences Ltd](https://www.sectoralpha.in/stocks/cohance-lifesciences-ltd) ₹16,999 crore
6. [Syngene International Ltd](https://www.sectoralpha.in/stocks/syngene-international-ltd) ₹16,256 crore
7. [Jubilant Pharmova Ltd](https://www.sectoralpha.in/stocks/jubilant-pharmova-ltd) ₹14,716 crore

[All 24 Pharma - API & CRAMS companies, largest first](https://www.sectoralpha.in/sectors/pharma-api-crams#all-companies)

### Companies close in size in other industries

1. [Castrol India Ltd](https://www.sectoralpha.in/stocks/castrol-india-ltd) ₹18,596 crore · Lubricants
2. [Aadhar Housing Finance Ltd](https://www.sectoralpha.in/stocks/aadhar-housing-finance-ltd) ₹18,417 crore · Finance - Housing
3. OneSource Specialty Pharma Ltd ₹17,924 crore
4. [EIH Ltd](https://www.sectoralpha.in/stocks/eih-ltd) ₹17,907 crore · Hotels
5. [Pine Labs Ltd](https://www.sectoralpha.in/stocks/pine-labs-ltd) ₹17,697 crore · E-Commerce - Platform - Utility

## What else do people ask about OneSource Specialty Pharma? ### What is OneSource Specialty Pharma's share price today? OneSource Specialty Pharma Ltd's share price is ₹1,568.70, −15.4% over the past year. The whole company is worth ₹17,989 Cr on the market. In the last 52 weeks it traded between ₹1,114 to ₹1,838; today it is 63% of the way up from the low, 1.3% below its 200-day average (as of 3 November 2026). ### What were OneSource Specialty Pharma's latest quarterly results? OneSource Specialty Pharma Ltd reported revenue of ₹516 Cr and net profit of ₹57.0 Cr for the Sep 2026 quarter. Revenue rose 37.2% and profit rose 470.0% compared with a year earlier. Earnings per share were ₹5.01. The operating margin was 32.0%, 4.0 percentage points higher than a year earlier (as of 3 November 2026). ### What is OneSource Specialty Pharma's market cap? OneSource Specialty Pharma Ltd's market capitalisation is ₹17,989 Cr at a share price of ₹1,568.70. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is OneSource Specialty Pharma performing? OneSource Specialty Pharma Ltd's share price has been falling for 11 weeks. In its latest quarter, revenue rose 37.2% and profit rose 470.0% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 2 weeks running (as of 3 November 2026). ### Will OneSource Specialty Pharma's share price go up? This page does not forecast OneSource Specialty Pharma Ltd's share price. What it shows instead: the share price is ₹1,568.70, and it has been falling for 11 weeks. Its P/E of 1,572.7× is higher than 100% of its own last 2 years (as of 3 November 2026). ### Who owns OneSource Specialty Pharma? Promoters own 30.5% of OneSource Specialty Pharma Ltd, foreign institutions 19.4%, domestic institutions 24.2% and the public 25.9% (latest quarter). The biggest change over the last two years: Domestic institutions raised their stake by 11.6 percentage points over 7 quarters (as of 3 November 2026). ### Does OneSource Specialty Pharma have too much debt? No, OneSource Specialty Pharma Ltd has little debt: its debt is 0.22× its equity, and its operating profit is 3 times its interest bill. FY26 borrowings were ₹1,276 Cr against equity of ₹5,831 Cr. So the returns on this page come from the business, not borrowed money (as of 3 November 2026). ### Where is OneSource Specialty Pharma in its business cycle? OneSource Specialty Pharma Ltd's FY26 operating margin was 21.0%, against a 6-year range of −415.0% to 32.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 32.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the OneSource Specialty Pharma story? The main question: results are strong, and the P/E is higher than 100% of its own history. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is OneSource Specialty Pharma a stock worth studying right now? What the numbers show: OneSource Specialty Pharma Ltd's results are improving, and its P/E is near the top of its own history, higher than 100% of past readings. The main open question: whether earnings grow enough to match the multiple. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a OneSource Specialty Pharma share price forecast for 2026? What management itself guided: FY28 revenue USD 400M with reported operating profit USD 160M reaffirmed. ## Lists

- Small & mid cap stocks: https://www.sectoralpha.in/small-cap-stocks-india
- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.